Thursday, October 04, 2018 6:10:41 AM
All they've done is capitalize on the benefits of switching someone with CHF and COPD from and ACE inhibitor to an ARB, any ARB.
These days pretty much everyone with CHF also has COPD.
They are using a massive marketing campaign with many TV commercials to try and convince people that Entresto is something new when it's mainly comprised of the same drug (valsartan) that was their once big time seller they called DIOVAN, they recently lost patent protection on.
Their trial did not include a true head to head comparison of valsartan vs valsartan/sacubitril.
They try and convince people that using an ARB instead of an ACE inhibitor for CHF is something new, ARB's have been around for years and there are many examples from many companies.
Doctors and insurance companies will soon get wise to this and Entresto sales will plummet.
Never before in history has a pharma tried such an attempt at repackaging and re-patenting a drug that they lost patent protection on in this manner, people will catch on eventually.
Recent NVS News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/16/2024 12:44:34 PM
- Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 09/16/2024 12:12:17 PM
- Intel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion Deal • IH Market News • 09/16/2024 10:03:27 AM
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget • Business Wire • 08/28/2024 04:16:00 PM
- Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples • Business Wire • 08/28/2024 04:07:00 PM
- Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab • Business Wire • 08/28/2024 04:06:00 PM
- Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation • Business Wire • 08/28/2024 10:58:00 AM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:30:06 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/13/2024 08:31:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 07:30:35 PM
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) • PR Newswire (US) • 08/07/2024 11:38:00 PM
- Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News • IH Market News • 08/06/2024 09:44:42 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/02/2024 08:30:48 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:30:53 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/31/2024 08:30:44 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/30/2024 08:30:54 PM
- Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:54 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/25/2024 08:30:58 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/18/2024 08:30:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:09:04 AM
- TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge • IH Market News • 07/18/2024 09:53:54 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM